ornithine aspartate
Selected indexed studies
- Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease. (Dig Dis, 2019) [PMID:30016770]
- Intravenous versus oral 'L-ornithine-L-aspartate' in overt hepatic encephalopathy: a randomized comparative study. (Sci Rep, 2024) [PMID:38789596]
- L-Ornithine L-Aspartate (LOLA) for the Treatment of Hepatic Encephalopathy in Cirrhosis: Novel Insights and Translation to the Clinic. (Drugs, 2019) [PMID:30706421]
_Worker-drafted node — pending editorial review._
Connections
ornithine aspartate is a side effect of
Sources
- Hepatoprotection by L-Ornithine L-Aspartate in Non-Alcoholic Fatty Liver Disease. (2019) pubmed
- Intravenous versus oral 'L-ornithine-L-aspartate' in overt hepatic encephalopathy: a randomized comparative study. (2024) pubmed
- L-Ornithine L-Aspartate (LOLA) for the Treatment of Hepatic Encephalopathy in Cirrhosis: Novel Insights and Translation to the Clinic. (2019) pubmed
- L-Ornithine L-Aspartate (LOLA) for Hepatic Encephalopathy in Cirrhosis: Results of Randomized Controlled Trials and Meta-Analyses. (2019) pubmed
- Efficacy of L-ornithine L-aspartate for minimal hepatic encephalopathy in patients with cirrhosis: A meta-analysis of randomized controlled trials. (2024) pubmed
- L-Aspartate, L-Ornithine and L-Ornithine-L-Aspartate (LOLA) and Their Impact on Brain Energy Metabolism. (2020) pubmed
- L-Ornithine L-Aspartate for the Treatment of Sarcopenia in Chronic Liver Disease: The Taming of a Vicious Cycle. (2019) pubmed
- L-ornithine L-aspartate for prevention and treatment of hepatic encephalopathy in people with cirrhosis. (2018) pubmed
- Pharmacokinetic and Pharmacodynamic Properties of L-Ornithine L-Aspartate (LOLA) in Hepatic Encephalopathy. (2019) pubmed
- L-Ornithine-l-aspartate in the management of hepatic encephalopathy: a meta-analysis. (2009) pubmed